ORPHERA Signal

Drug–Disease Go/No-Go
in One Card.

Enter a drug and a rare disease. Get a standardized evidence card with literature, patents, clinical trials, regulatory status, and competitive landscape — scored and ready for decision-making.

$2,000 per card
Order Now →
Sample Output
What you receive.

Sirolimus × Progeria (HGPS)

✓ GO — Strong Evidence
CREST Rank 4/ 1,170 drugs
Top 0.3%percentile
p = 0.001permutation test
CREST Value0.847
CREST Engine Score
8 7 5 4★ 6 9 11 12 0.847
CREST value 0.847 (Rank 4)
Library screened 1,170 drugs
Permutation p-value p = 0.001
Percentile Top 0.3%
Literature
PubMed results 47 papers
Clinical evidence Phase 1/2 completed
Mechanism support Strong (mTOR)
Key reference Gordon 2018, NEJM
Evidence Strength
84 / 100
Composite score across literature, mechanism, and clinical validation dimensions.
IP & Regulatory
Existing use-patent Partial coverage
Orphan designation Granted (FDA)
505(b)(2) eligible Yes
New use patent window Open
Competitive Landscape
Active trials 3 ongoing
Competing drugs Lonafarnib (approved)
Market gap Combination therapy
Patient prevalence (US) ~400
What's included
📄 Detailed analysis 📚 Source citations 🎯 Strategic recommendations ⚠️ Risk matrix 12 pages total
Process
Three steps. 48 hours.
1

Submit & Pay

Enter your drug–disease pair. Complete $2,000 payment via PayPal. Secure, instant.

2

Analyze

Our team runs a comprehensive scan across PubMed, patent databases, ClinicalTrials.gov, and FDA orphan drug records.

3

Deliver

You receive a standardized Evidence Card via email — scored, sourced, and ready for your pipeline decision.

Deliverable
Every card covers six dimensions.
✓

Literature Review

Relevant PubMed publications, mechanism of action evidence, preclinical and clinical data summary.

✓

Patent Landscape

Existing use-patents, expiry dates, whitespace opportunities, freedom-to-operate assessment.

✓

Clinical Trial Status

Active, completed, and terminated trials. Phase, sponsor, enrollment, primary endpoints.

✓

Regulatory Pathway

Orphan drug designation status, 505(b)(2) eligibility, regulatory precedents.

✓

Competitive Intelligence

Competing programs, market positioning, differentiation opportunities.

✓

Go/No-Go Verdict

Standardized scoring across all dimensions. Clear recommendation with risk matrix and next steps.

Order
Request your Evidence Card.
Generic name preferred. Include brand name if applicable.
Be as specific as possible (subtype, gene if known).
Payment
Evidence Card × 1 $2,000
🔒 Secured by PayPal. All major cards accepted.

You'll be redirected to PayPal for secure payment ($2,000). Analysis begins immediately upon payment. Delivery within 48 hours.

FAQ
Common questions.
What exactly do I get?
A standardized PDF report (10–15 pages) covering literature, patents, clinical trials, regulatory pathway, competitive landscape, and a scored Go/No-Go verdict with strategic recommendations.
How long does it take?
48 hours from payment confirmation. Rush delivery (24 hours) available upon request.
Is this limited to rare diseases?
We specialize in rare disease drug repurposing, but Evidence Cards are available for any drug–disease combination where public data exists.
Can I order multiple cards?
Yes. Batch orders of 5+ cards receive a 15% discount. Contact us for batch pricing.
Is the data AI-generated?
Every data point is sourced from PubMed, ClinicalTrials.gov, USPTO/KIPRIS patent databases, and FDA records. AI assists in synthesis and scoring, but all sources are cited and verifiable.
What if there's no relevant data?
If our scan finds insufficient data to produce a meaningful card, we'll notify you within 24 hours and issue a full refund.